Abstract

Background: Glucocorticoids (GCs) are often the first-line therapy for autoimmune diseases including many neurological conditions. Their use is commonly associated with complications and comorbidities. These include both immediate and long-term complications that are often related to the dose and cumulative dose of GCs. The aim: The aim of this study to show about safety and long term effects of glucocorticoids in treatment of inflammatory rheumatic disease. Methods: By the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020, this study was able to show that it met all of the requirements. This search approach, publications that came out between 2014 and 2024 were taken into account. Several different online reference sources, like Pubmed, SagePub, and Sciencedirect were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done. Result: Eight publications were found to be directly related to our ongoing systematic examination after a rigorous three-level screening approach. Subsequently, a comprehensive analysis of the complete text was conducted, and additional scrutiny was given to these articles. Conclusion: Glucocorticoids are effective drugs for many rheumatic diseases. However, there are serious adverse effects that can ensue. These are often dose related and related to the duration of therapy. Several of the complications occur in patients already at risk for these adverse events. The adverse effects, such as weight gain, osteoporosis, fracture, osteonecrosis, infections, ocular complications, cardiovascular effects, hyperglycemia, etc.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.